Skip to main content

Clinical trial DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2

An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients

Cancers
Organ Multiple
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 1
Academic trial Non
Sponsor Celyad
EudraCT Identifier 2018-000205-22
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03466320
Inclusion criteria any line
Last update